We are pleased to report a successful 2022, as we were able to manage our business to deliver 17% revenue growth and continued positive cash flow from operations.
Despite ongoing external challenges, we made significant progress toward our mission of providing quality products to improve patients’ quality of life.
Our newly acquired Sancuso® franchise joined our legacy Caldolor®, Kristalose® and Vibativ® brands to help a growing number of patients during the year.
We acquired Sancuso in early 2022 from the U.S. affiliate of Japan-based Kyowa Kirin. It’s the only FDA-approved prescription patch for the prevention of nausea and vomiting in cancer patients receiving certain chemotherapy treatments. During the year, we successfully transitioned Sancuso from Kyowa Kirin and we’re supporting the brand through our new sales division – Cumberland Oncology.
Other company highlights from 2022 include:
As always, our success was made possible by our dedicated Cumberland team. We will continue to execute on our strategy of building a portfolio of differentiated FDA approved brands.
We look forward to keeping you updated on our progress and developments.
2022 Company Highlights
We are pleased to report a successful 2022, as we were able to manage our business to deliver 17% revenue growth and continued positive cash flow from operations.
Despite ongoing external challenges, we made significant progress toward our mission of providing quality products to improve patients’ quality of life.
Our newly acquired Sancuso® franchise joined our legacy Caldolor®, Kristalose® and Vibativ® brands to help a growing number of patients during the year.
We acquired Sancuso in early 2022 from the U.S. affiliate of Japan-based Kyowa Kirin. It’s the only FDA-approved prescription patch for the prevention of nausea and vomiting in cancer patients receiving certain chemotherapy treatments. During the year, we successfully transitioned Sancuso from Kyowa Kirin and we’re supporting the brand through our new sales division – Cumberland Oncology.
Other company highlights from 2022 include:
As always, our success was made possible by our dedicated Cumberland team. We will continue to execute on our strategy of building a portfolio of differentiated FDA approved brands.
We look forward to keeping you updated on our progress and developments.